IER2

Across TCGA pan-cancer cohorts, IER2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IER2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IER2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IER2 expression acts as an unfavorable survival marker.

STAD, HNSC, and SKCM are the cancer types where IER2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →
HNSC	DFS	Median	All	0.122	0.696	<.001	45	view →
SKCM	OS	Median	All	0.291	0.784	<.001	21	view →
ESCA	OS	Median	All	0.022	0.701	<.001	12	view →
SARC	DFS	Median	All	0.154	0.614	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IER2–STAD (OS)

Open the STAD breakdown →